11/9/2010 - Up today with above average volume, rallying up from support at prior chart resistance in the $20 area and its 200 DMA line that now define important support levels to watch. Based on its technical breakdown this week it will be dropped from the Featured Stocks list tonight.
11/8/2010 10:01:51 AM - G - Gapped down today and violated its 50 DMA line following earnings news. The technical breach of near-term support raised concerns and triggered a technical sell signal. Old chart resistance in the $20 area and its 200 DMA line define the next important support levels to watch.
11/4/2010 5:04:00 PM - G - Holding its ground stubbornly since its "negative reversal" on 10/22/10 was noted. Prior chart highs near $23.50 define near-term support above its 50 DMA line. Its currently low P/E Ratio of 8 (60% X S&P 500) might attract the interest of "value" players, but the low P/E and Street estimates calling for only +3% earnings growth in FY '11 raise concerns with respect to its future earnings outlook.
10/29/2010 5:50:28 PM - G - Small loss on above average volume today, a sign of distributional pressure. Holding its ground stubbornly since its "negative reversal" on 10/22/10 was noted. Prior chart highs near $23.50 define near-term support above its 50 DMA line. Its currently low P/E Ratio of 8 (only 60% X S&P 500) might attract the interest of "value" players, but the low P/E and Street estimates calling for only +3% earnings growth in FY '11 raise concerns with respect to its future earnings outlook.
10/27/2010 5:30:02 PM - G - Holding its ground stubbornly with volume totals cooling since its "negative reversal" on 10/22/10 was noted. Prior chart highs near $23.50 define near-term support above its 50 DMA line. Its currently low P/E Ratio of 8 (only 60% X S&P 500) might attract the interest of "value" players, but the low P/E and Street estimates calling for only +3% earnings growth in FY '11 raise concerns with respect to its future earnings outlook.
10/22/2010 4:16:48 PM - G - Volume was above average today with a worrisome "negative reversal" after a gap up, as it finished near the session low with a loss. Prior chart highs near $23.50 define near-term support above its 50 DMA line.
10/21/2010 2:45:07 PM - G - Volume totals are still cooling while consolidating toward prior chart highs near $23.50 that define near-term support above its 50 DMA line.
10/20/2010 4:24:15 PM - G - Volume totals have been cooling while consolidating toward prior chart highs after a burst of buying last week drove it to all-time highs. Prior highs near $23.50 define near-term support above its 50 DMA line.
10/19/2010 4:38:50 PM - G - Quietly consolidating toward prior chart highs after a burst of buying last week drove it to all-time highs. Prior highs near $23.50 define near-term support above its 50 DMA line.
10/18/2010 4:24:45 PM - G - Quietly consolidating after a burst of buying last week drove it to all-time highs. Prior highs near $23.50 define near-term support above its 50 DMA line.
10/15/2010 6:23:29 PM - G - Quietly consolidating after a burst of buying earlier this week drove it to all-time highs. Prior highs near $23.50 define near-term support above its 50 DMA line.
10/12/2010 5:03:47 PM - G - Hit another new high today, and its color code is changed to green after rallying more than +5% above recent chart highs. Gapped up on 10/11/10 for a new high following a consolidation near its 10-week moving average line.
10/12/2010 1:19:21 PM - Y - Hit another new high today. Gapped up on 10/11/10 for a new high following a consolidation near its 10-week moving average line. Color code was changed to yellow and it was noted - "Considered buyable up to +5% above its latest high ($23.53 X 1.05 or $24.81) as a secondary buy point following its earlier technical breakout. A new pivot point is not cited as a new base was not formed."
10/11/2010 1:01:13 PM - Y - Gapped up today, rallying above prior highs following a consolidation near its 10-week moving average line. Color code is changed to yellow, as it may considered buyable up to +5% above its latest high ($23.53 X 1.05 or $24.81) as a secondary buy point following its earlier technical breakout. A new pivot point is not cited as a new base was not formed.
10/8/2010 3:56:32 PM - G - Up today with below average volume for a 4th consecutive small gain. Signs of more worrisome distributional pressure contributed to its slump near prior highs and its 50 DMA line defining chart support in the $20-21 area.
10/5/2010 6:19:58 PM - G - Gapped up today for a small gain with below average volume. Signs of more worrisome distributional pressure contributed to its slump near prior highs and its 50 DMA line defining chart support in the $20-21 area.
10/1/2010 4:32:56 PM - G - Gapped down today for a loss with heavy volume, a sign of more worrisome distributional pressure. Slumping near prior highs and its 50 DMA line defining chart support in the $20-21 area.
9/28/2010 4:46:01 PM - G - Today it endured more distributional pressure. Extended from its latest base, its prior highs define chart support in the $20-21 area.
9/27/2010 5:37:20 PM - G - Enduring mild distributional pressure, it is extended from its latest base. Prior highs define chart support in the $20-21 area.
9/20/2010 5:17:09 PM - G - Gain today with near average volume for yet another new all-time high. Color code was changed to green after getting extended from its prior base. (Featured price, pivot point, and max buy data are adjusted -$8.50 following recent cash dividend.)
9/17/2010 4:47:24 PM - G - Gain today with average volume for a new all-time high. Color code is changed to green as it gets extended from its prior base. (Price data will be adjusted downward to account for the recent special $8.50 cash dividend dividend impacting its share price as of 9/09/10 trading, so the "max buy" level $30.81 -$8.50 equals $22.31.
9/15/2010 5:31:47 PM - Y - Volume was light today as it rallied to a new all-time high. (Price data will be adjusted downward to account for the recent special $8.50 cash dividend dividend impacting its share price as of 9/09/10 trading, so the "max buy" level $30.81 -$8.50 equals $22.31, pennies from today's close.
9/9/2010 6:53:33 PM - Y - Volume was heavy today as it rallied to a new all-time high. Price data will be adjusted to account for a "quirky" dividend effective as of today's trading. WCRX was featured in yellow in the mid-day report on 8/23/10 rising from a cup shaped base.
9/8/2010 6:41:25 PM - Y - Volume was above average today as it encountered distributional pressure. It remains perched near its pivot point. WCRX was featured in yellow in the mid-day report on 8/23/10 rising from a cup shaped base.
9/1/2010 2:10:08 PM - Y - Volume totals have been cooling while it remains perched near its pivot point. It was featured in yellow in the mid-day report on 8/23/10 rising from a cup shaped base.
8/27/2010 6:24:02 PM - Y - Posted a gain today with heavy volume, yet it ended the session still below its pivot point after 2 prior losses on lighter volume. It was featured in yellow in the mid-day report on 8/23/10 (read here), rising from a cup shaped base.
8/25/2010 5:55:27 PM - Y - Loss today with above average volume led to a close below its pivot point. It was featured in yellow in the mid-day report on 8/23/10 (read here), rising from a cup shaped base formed since it was noted in the 5/06/10 mid-day report - "Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2009. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09." (Correction notice: Dec '10 references in prior notes should have been Dec '09)
8/25/2010 11:03:04 AM - Y - Pulling back further today, sinking below its pivot point after reversing from an all-time high on the prior session and enduring some distributional pressure amid widespread market weakness. It was featured in yellow in the mid-day report on 8/23/10 (read here), rising from a cup shaped base formed since it was noted in the 5/06/10 mid-day report - "Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2009. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09." (Correction notice: Dec '10 references in prior notes should have been Dec '09)
8/24/2010 8:12:49 PM - Y - Closed near the session low today, after initially gapping up and hitting a new all-time high, enduring distributional pressure amid widespread market weakness. It was featured in yellow in the mid-day report on 8/23/10 (read here), rising from a cup shaped base formed since it was noted in the 5/06/10 mid-day report - "Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2010. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09."
8/24/2010 1:23:29 PM - Y - Gapped up today and hit another new all-time high. It was featured in yellow in the mid-day report on 8/23/10 (read here), rising from a cup shaped base formed since it was noted in the 5/06/10 mid-day report - "Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2010. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09."
8/23/2010 4:57:00 PM - Y - Reported huge sales revenues and earnings increases in the Mar and Jun '10 quarters, so fundamentals are currently strong. It was featured in yellow in the mid-day report while hitting a new all-time high today (read here), rising from a cup shaped base formed since it was noted in the 5/06/10 mid-day report - "Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2010. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09."
8/23/2010 1:38:23 PM - Y - Reported huge sales revenues and earnings increases in the Mar and Jun '10 quarters, so fundamentals are currently strong and it is hitting a new all-time high today. Rising from a cup shaped base formed since it was noted in the 5/06/10 mid-day report - "Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2010. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09."
5/6/2010 1:27:21 PM - Pulling back near its 50 DMA line. Noted in the 4/26/10 mid-day report - "Reversed from today's earlier highs after a gap up helped it trade above the 3/08/10 high of the long flat base that has formed since it was noted in the mid-day report on 1/29/10. Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2010. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09."
4/26/2010 1:23:35 PM - It has reversed from today's earlier highs after a gap up helped it trade above the 3/08/10 high of the long flat base that has formed since it was noted in the mid-day report on 1/29/10. Earnings and sales revenues history has been below guidelines of the fact-based system, yet showed drastic increases in the quarter ended Dec 31, 2010. It encountered stubborn resistance in the $29 area since the high-ranked firm hailing from the Medical - Ethical Drugs industry was noted in a handful of Q4 2009 mid-day reports after announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09.
1/29/2010 12:57:35 PM - Earnings and sales revenues growth has been sub par. Gapped up above its 50 DMA line today after providing guidance, a sign it is finding support near that short-term average. It has been strong since announcing plans to buy Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09.
12/10/2009 12:49:42 PM - Earnings and sales revenues growth has been sub par. Rallying for a new all-time high today, it has been trending higher and found support near its 50 DMA line since its big gap up on news it was buying Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09.
12/1/2009 12:53:53 PM - Earnings and sales revenues growth has been sub par. It has been trending higher and found support near its 50 DMA line since news it was buying Procter & Gamble Co's prescription drug business in a deal first announced 8/24/09.
10/12/2009 1:00:08 PM - Three of its four latest quarters showed better than +25% earnings increases over the year ago period, however its sales revenues growth has been sub par. Gapped up today for another new all-time high. Buying Procter & Gamble Co's prescription drug business in a deal first announded 8/24/09.
10/8/2009 2:08:53 PM - Three of its four latest quarters showed better than +25% earnings increases over the year ago period, however its sales revenues growth has been sub par. Holding its ground since gaps up on 8/24/09 and 8/25/09 helped it blast to new all-time highs after announcing a deal to buy Procter & Gamble Co's prescription drug business for $3.1 Billion (read here).
8/27/2009 12:57:09 PM - Three of its four latest quarters showed better than +25% earnings increases over the year ago period, however its sales revenues growth has been sub par. Holding its ground since gaps up on 8/24/09 and 8/25/09 helped it blast to new all-time highs after announcing a deal to buy Procter & Gamble Co's prescription drug business for $3.1 Billion (read here).
8/25/2009 12:52:30 PM - Gapped up today following the prior session's big gap up gain after announcing a deal to buy Procter & Gamble Co's prescription drug business for $3.1 Billion (read here). Three of its four latest quarters showed better than +25% earnings increases over the year ago period, however its sales revenues growth has been sub par.
12/20/2004 12:35:38 PM - Sales history questionable.
12/17/2004 12:57:22 PM - Sales history questionable.
12/14/2004 12:37:53 PM - Sales history questionable.
12/13/2004 1:00:51 PM - Sales history questionable.
12/7/2004 12:49:16 PM - Sales history questionable.
12/6/2004 12:30:16 PM - Sales history questionable.
11/12/2004 12:57:46 PM - No base.
11/5/2004 12:37:43 PM - No base.
10/29/2004 1:00:00 PM - No base.
10/28/2004 1:00:56 PM - No base.
10/27/2004 12:40:00 PM - No base.
10/25/2004 1:00:00 PM - No base.